RNAC 8-K: SEC filing

Cartesian Therapeutics

Filed with the SEC on Nov 5, 2026 · accession 0001453687-26-000110

RNAC filed a 8-K (current report) with the SEC on Nov 5, 2026. Cartesian Therapeutics reported Q3 2026 financial results with a net loss of $11.5 million and provided a business update highlighting progress in its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with data expected in 1Q27 and a BLA filing planned for mid-2027. The stock moved -0.6% by the first close after the filing.

Summary of the filing

Cartesian Therapeutics reported Q3 2026 financial results with a net loss of $11.5 million and provided a business update highlighting progress in its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with data expected in 1Q27 and a BLA filing planned for mid-2027. The company ended the quarter with approximately $124.7 million in cash, expected to fund operations into 2028.

For details, click here →How to read a 8-K →

Key details

Cash, cash equivalents and restricted cash as of September 30, 2026$124.7M

Net loss for Q3 2026$11.5M

Research and development expenses for Q3 2026$15.6M

General and administrative expenses for Q3 2026$9.4M

Net loss per share allocable to common stockholders (basic) for Q3 2026$0

Initial tranche of non-dilutive financing from K2 HealthVentures$50.0M

Amount raised year to date through at-the-market offering program$22.8M

IssuerCartesian Therapeutics, Inc.

PartnerWestGene BioPharma

Financing providerK2 HealthVentures

President and chief executive officerCarsten Brunn, Ph.D.

How RNAC stock reacted

Close before

$6.82

Nov 4, 2026

First close after

-0.59%

$6.78

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for RNAC, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RNAC?

Click here

Frequently asked questions

What did RNAC file with the SEC on Nov 5, 2026?

RNAC filed a 8-K (SEC filing). Cartesian Therapeutics reported Q3 2026 financial results with a net loss of $11.5 million and provided a business update highlighting progress in its Phase 3 AURORA trial of Descartes-08 in myasthenia gravis, with data expected in 1Q27 and a BLA filing planned for mid-2027. The company ended the quarter with approximately $124.7 million in cash, expected to fund operations into 2028.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did RNAC stock react to this filing?

RNAC closed at $6.82 before the filing and $6.78 on Nov 5, 2026 (-0.59%).

Other RNAC SEC filings

Get alerts when RNAC files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days

RNAC overview RNAC analysis RNAC news Latest SEC filings